This is in line with previous preclinical work that suggested combination activity of chemotherapeutic agents with ibrutinib in DLBCL by disruption of NF-κB signaling and decreased expression of antiapoptotic proteins by ibrutinib re-sensibilizing B-cells to undergo apoptosis [22]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.